BerandaONC • TSE
add
Oncolytics Biotech Inc
Tutup sebelumnya
$1,24
Rentang tahun
$0,45 - $2,08
Kapitalisasi pasar
110,14 jt CAD
Volume Rata-Rata
224,55 rb
Rasio P/E
-
Hasil dividen
-
Berita pasar
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (CAD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | — | — |
Biaya operasional | 7,00 jt | -19,79% |
Laba bersih | -6,69 jt | 3,00% |
Margin laba bersih | — | — |
Penghasilan per saham | -0,08 | 11,11% |
EBITDA | -6,97 jt | 19,83% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
| (CAD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 15,30 jt | -48,31% |
Total aset | 19,70 jt | -43,30% |
Total liabilitas | 13,21 jt | 12,11% |
Total ekuitas | 6,49 jt | — |
Saham yang beredar | 88,82 jt | — |
Harga terhadap nilai buku | 15,50 | — |
Tingkat pengembalian aset | -87,73% | — |
Tingkat pengembalian modal | -240,66% | — |
Arus Kas
Perubahan kas bersih
| (CAD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -6,69 jt | 3,00% |
Kas dari operasi | -6,50 jt | 13,00% |
Kas dari investasi | — | — |
Kas dari pembiayaan | 5,89 jt | 293,98% |
Perubahan kas bersih | -639,00 rb | 87,96% |
Arus kas bebas | -4,25 jt | 22,67% |
Tentang
Oncolytics Biotech Inc. is a Canadian company headquartered in Calgary, Alberta, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that: induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. Wikipedia
Didirikan
1998
Kantor pusat
Karyawan
28
